Olivier M. Sanchez
Expertise in
9
conditions

Olivier M. Sanchez

Paris, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
9
conditions
Paris, FR 
OverviewLocationsClinical Research

Overview

Olivier Sanchez practices in Paris, France. Mr. Sanchez is highly rated in 9 conditions, according to our data. His top areas of expertise are Pulmonary Embolism, Venous Thromboembolism (VTE), Deep Vein Thrombosis, Embolectomy, and Thrombectomy.

His clinical research consists of co-authoring 236 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Paris, France
Other Locations
Saint-etienne-de-valoux, France
France
Saint-etienne, France
Colombes, 92700, France
Nancy, 54000, France
Georges, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Computerized Registry of Patients With Venous Thromboembolism (RIETE)
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
Enrollment Status: Recruiting
Publish Date: September 24, 2025
Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension
Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: October 18, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism. The RENOVE Open-label, Randomized, Controlled Trial.
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism. The RENOVE Open-label, Randomized, Controlled Trial.
Enrollment Status: Completed
Publish Date: December 28, 2023
Intervention Type: Drug
Study Drug: Direct Oral Anticoagulants
Study Phase: Phase 3
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
Enrollment Status: Terminated
Publish Date: October 19, 2022
Intervention Type: Drug
Study Drugs: Apixaban, Rivaroxaban, Heparin, VKA
Study Phase: Phase 3
Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: Prospective, Multicenter Cohort Study PEAGE
Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: Prospective, Multicenter Cohort Study PEAGE
Enrollment Status: Completed
Publish Date: August 25, 2022
Intervention Type: Other
Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study
Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study
Enrollment Status: Completed
Publish Date: July 05, 2022
Intervention Type: Drug
Study Drug: Enoxaparin
Study Phase: Phase 3
Frequency and Risk Factors of the Lung High Blood Pressure Post-embolique in the Fall of a First Episode of Idiopathic Pulmonary Embolism. Study PADIS HTP
Frequency and Risk Factors of the Lung High Blood Pressure Post-embolique in the Fall of a First Episode of Idiopathic Pulmonary Embolism. Study PADIS HTP
Enrollment Status: Terminated
Publish Date: July 20, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 6 Less Clinical Trials

236 Total Publications

Dexamethasone Suppresses Endotheliopathy and Endothelial-Induced Coagulopathy in COVID-19.
Dexamethasone Suppresses Endotheliopathy and Endothelial-Induced Coagulopathy in COVID-19.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: September 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sanchez's expertise for a condition
ConditionClose
View All 29 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile